PETALUMA, CA--(Marketwired - Feb 3, 2015) - Streetwise Reports/The Life Sciences Report released notes from the 2015 Small-Cap Biotech Watchlist panel discussion, which occurred at the Biotech Showcase in San Francisco on January 13. The Watchlist companies selected by top sector analysts include Can-Fite BioPharma Ltd. (NYSE MKT: CANF) and Sunesis Pharmaceuticals (NASDAQ: SNSS). The panel focused on companies they believe should see significant gains in 2015.
This marks the third year Streetwise Reports has tracked a basket of analyst-selected companies in real time throughout the year. "Our publications specialize in sharing insights from top experts in each sector; this adds the dynamic element of a live, graphic way to watch those ideas play out over time," explained President Karen Roche.
This year, the panel featured Mara Goldstein, managing director at Cantor Fitzgerald; Reni Benjamin, head of equity research at H.C. Wainwright & Co.; Bert Hazlett, managing director of equity research at Ladenburg Thalmann & Co.; Joe Pantginis, head of biotechnology research at Roth Capital Partners; and George Zavoico, managing director of equity research at MLV & Co.
Readers can subscribe to The Life Sciences Report for free to get updates on the Watchlist and future interviews.
Streetwise Reports publishes The Life Sciences Report, in addition to The Gold Report and The Energy Report. These reports feature interviews with experts talking about macro-trends in and specific investing ideas in those sectors. Streetwise interviews are syndicated to major retail and institutional investing sites.
Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multibillion dollar markets in the treatment of cancer, inflammatory and other diseases. The company is in Phase 2/3 trials for psoriasis and Phase 2 trials for liver cancer. Study design for a Phase 3 trial in rheumatoid arthritis has been completed. Can-Fite has been granted orphan drug designation by the U.S. FDA for its liver cancer drug, which is approved for compassionate use by Israel's Ministry of Health.
Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.